{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:27:03Z","timestamp":1793824023435,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Silesia","award":["KNW-1-007\/N\/8\/K"],"award-info":[{"award-number":["KNW-1-007\/N\/8\/K"]}]},{"name":"Silesia University of Technology","award":["Grant for developing and maintaining research potential"],"award-info":[{"award-number":["Grant for developing and maintaining research potential"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease is associated with an increased cardiovascular disease (CVD) risk, although the exact mechanism(s) are less clear. Moreover, the relationship between newly redefined metabolic-associated fatty liver disease (MAFLD) and CVD risk has been poorly investigated. Data-driven machine learning (ML) techniques may be beneficial in discovering the most important risk factors for CVD in patients with MAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this observational study, the patients with MAFLD underwent subclinical atherosclerosis assessment and blood biochemical analysis. Patients were split into two groups based on the presence of CVD (defined as at least one of the following: coronary artery disease; myocardial infarction; coronary bypass grafting; stroke; carotid stenosis; lower extremities artery stenosis).<\/jats:p>\n                    <jats:p>The ML techniques were utilized to construct a model which could identify individuals with the highest risk of CVD. We exploited the multiple logistic regression classifier operating on the most discriminative patient\u2019s parameters selected by univariate feature ranking or extracted using principal component analysis (PCA). Receiver operating characteristic (ROC) curves and area under the ROC curve (AUC) were calculated for the investigated classifiers, and the optimal cut-point values were extracted from the ROC curves using the Youden index, the closest to (0, 1) criteria and the Index of Union methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 191 patients with MAFLD (mean age: 58, SD: 12\u00a0years; 46% female), there were 47 (25%) patients who had the history of CVD. The most important clinical variables included hypercholesterolemia, the plaque scores, and duration of diabetes. The five, ten and fifteen most discriminative parameters extracted using univariate feature ranking and utilized to fit the ML models resulted in AUC of 0.84 (95% confidence interval [CI]: 0.77\u20130.90,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), 0.86 (95% CI 0.80\u20130.91,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and 0.87 (95% CI 0.82\u20130.92,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), whereas the classifier fitted over 10 principal components extracted using PCA followed by the parallel analysis obtained AUC of 0.86 (95% CI 0.81\u20130.91,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The best model operating on 5 most discriminative features correctly identified 114\/144 (79.17%) low-risk and 40\/47 (85.11%) high-risk patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A ML approach demonstrated high performance in identifying MAFLD patients with prevalent CVD based on the easy-to-obtain patient parameters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-022-01672-9","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T11:02:58Z","timestamp":1668250978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Risk factors for cardiovascular disease\u00a0in patients with metabolic-associated fatty liver disease: a machine learning approach"],"prefix":"10.1186","volume":"21","author":[{"given":"Karolina","family":"Dro\u017cd\u017c","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Nabrdalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kwiendacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Olejarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Tomasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Bartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Nalepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Gumprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"1672_CR1","doi-asserted-by":"publisher","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy,\nJapan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904.\nhttps:\/\/doi.org\/10.1016\/j.jhep.2018.05.036.","DOI":"10.1016\/j.jhep.2018.05.036"},{"issue":"1","key":"1672_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"1672_CR3","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691\u2013700.","journal-title":"J Clin Endocrinol Metab"},{"key":"1672_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691\u2013705.","journal-title":"Gut"},{"issue":"6","key":"1672_CR5","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"G Marchesini","year":"2016","unstructured":"Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402.","journal-title":"J Hepatol"},{"issue":"7","key":"1672_CR6","first-page":"434","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434\u20138.","journal-title":"Mayo Clin Proc"},{"key":"1672_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510380242","author":"BA Neuschwander-Tetri","year":"2003","unstructured":"Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37(5):1202\u20131219. https:\/\/doi.org\/10.1053\/jhep.2003.50193.","journal-title":"Hepatology"},{"issue":"1","key":"1672_CR8","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47-64.","journal-title":"J Hepatol"},{"issue":"7","key":"1672_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1.","journal-title":"Gastroenterology"},{"issue":"5","key":"1672_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","volume":"7","author":"N M\u00e9ndez-S\u00e1nchez","year":"2022","unstructured":"M\u00e9ndez-S\u00e1nchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388\u201390.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"1672_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Ahmed A, Despr\u00e9s J-P, Jha V, Halford JCG, Wei Chieh JT, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6(9):743\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1672_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","author":"N Chalasani","year":"2017","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"issue":"11","key":"1672_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115\u201328.","journal-title":"Hepatol Res"},{"issue":"3","key":"1672_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","volume":"38","author":"J Alharthi","year":"2022","unstructured":"Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251\u201360.","journal-title":"Curr Opin Gastroenterol"},{"issue":"25","key":"1672_CR15","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DCJ Goff","year":"2014","unstructured":"Goff DCJ, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RBS, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25):2935\u201359.","journal-title":"J Am Coll Cardiol"},{"issue":"9907","key":"1672_CR16","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(13)62388-0","volume":"382","author":"PM Ridker","year":"2013","unstructured":"Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet (London, England). 2013;382(9907):1762\u20135.","journal-title":"Lancet (London, England)"},{"issue":"14","key":"1672_CR17","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jama.2014.2630","volume":"311","author":"P Muntner","year":"2014","unstructured":"Muntner P, Colantonio LD, Cushman M, Goff DCJ, Howard G, Howard VJ, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311(14):1406\u201315.","journal-title":"JAMA"},{"issue":"14","key":"1672_CR18","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jama.2014.2632","volume":"311","author":"M Kavousi","year":"2014","unstructured":"Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, et al. Comparison of application of the ACC\/AHA guidelines, adult treatment panel III guidelines, and European society of cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416\u201323.","journal-title":"JAMA"},{"issue":"8","key":"1672_CR19","first-page":"598","volume":"38","author":"AP DeFilippis","year":"2017","unstructured":"DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, Kronmal RA, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular disease risk score in a modern mul. Eur Heart J. 2017;38(8):598\u2013608.","journal-title":"Eur Heart J"},{"issue":"1","key":"1672_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1186\/s12889-018-5806-x","volume":"18","author":"A Gheorghe","year":"2018","unstructured":"Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018;18(1):975. https:\/\/doi.org\/10.1186\/s12889-018-5806-x.","journal-title":"BMC Public Health"},{"issue":"1","key":"1672_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12890-022-02031-w","volume":"22","author":"Y Liang","year":"2022","unstructured":"Liang Y, Zhu C, Tian C, Lin Q, Li Z, Li Z, et al. Early prediction of ventilator-associated pneumonia in critical care patients: a machine learning model. BMC Pulm Med. 2022;22(1):250. https:\/\/doi.org\/10.1186\/s12890-022-02031-w.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"1672_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1053\/j.sart.2022.01.003","volume":"32","author":"CD Lopez","year":"2022","unstructured":"Lopez CD, Constant M, Anderson MJJ, Confino JE, Lanham NS, Jobin CM. Using machine learning methods to predict prolonged operative time in elective total shoulder arthroplasty. Semin Arthroplast JSES. 2022;32(3):452\u201361.","journal-title":"Semin Arthroplast JSES"},{"key":"1672_CR23","doi-asserted-by":"publisher","first-page":"104733","DOI":"10.1016\/j.ijmedinf.2022.104733","volume":"161","author":"S Jin","year":"2022","unstructured":"Jin S, Qin D, Liang B-S, Zhang L-C, Wei X-X, Wang Y-J, et al. Machine learning predicts cancer-associated deep vein thrombosis using clinically available variables. Int J Med Inform. 2022;161:104733.","journal-title":"Int J Med Inform"},{"issue":"5","key":"1672_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/ehjqcco\/qcab037","volume":"8","author":"GYH Lip","year":"2022","unstructured":"Lip GYH, Tran G, Genaidy A, Marroquin P, Estes C, Landsheft J. Improving dynamic stroke risk prediction in non-anticoagulated patients with and without atrial fibrillation: comparing common clinical risk scores and machine learning algorithms. Eur Hear journal Qual care Clin outcomes. 2022;8(5):548\u201356.","journal-title":"Eur Hear journal Qual care Clin outcomes"},{"issue":"22","key":"1672_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009476","volume":"7","author":"IA Kakadiaris","year":"2018","unstructured":"Kakadiaris IA, Vrigkas M, Yen AA, Kuznetsova T, Budoff M, Naghavi M. Machine learning outperforms ACC \/ AHA CVD risk calculator in MESA. J Am Heart Assoc. 2018;7(22): e009476.","journal-title":"J Am Heart Assoc"},{"key":"1672_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"issue":"9","key":"1672_CR27","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1515\/CCLM.2003.183","volume":"41","author":"RR Little","year":"2003","unstructured":"Little RR. Glycated hemoglobin standardization\u2013national glycohemoglobin standardization program (NGSP) perspective. Clin Chem Lab Med. 2003;41(9):1191\u20138.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"1672_CR28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/clinchem\/48.2.236","volume":"48","author":"M Nauck","year":"2002","unstructured":"Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002;48(2):236\u201354.","journal-title":"Clin Chem"},{"issue":"9","key":"1672_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"27","key":"1672_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007433","volume":"96","author":"W Xu","year":"2017","unstructured":"Xu W, Yu Q, Xie L, Chen B, Zhang L. Evaluation of Sysmex XN-1000 hematology analyzer for cell count and screening of malignant cells of serous cavity effusion. Medicine (Baltimore). 2017;96(27): e7433.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1672_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/jcla.20141","volume":"21","author":"AR Si\u015fman","year":"2007","unstructured":"Si\u015fman AR, K\u00fcme T, Ta\u015f G, Akan P, Tuncel P. Comparison and evaluation of two C-reactive protein assays based on particle-enhanced immunoturbidimetry. J Clin Lab Anal. 2007;21(2):71\u20136.","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"1672_CR32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1515\/CCLM.2008.159","volume":"46","author":"AJ van Gammeren","year":"2008","unstructured":"van Gammeren AJ, van Gool N, de Groot MJM, Cobbaert CM. Analytical performance evaluation of the Cobas 6000 analyzer - special emphasis on trueness verification. Clin Chem Lab Med. 2008;46(6):863\u201371.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"1672_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/rssb.12301","volume":"81","author":"E Dobriban","year":"2019","unstructured":"Dobriban E, Owen AB. Deterministic parallel analysis: an improved method for selecting factors and principal components. J R Stat Soc Ser B. 2019;81(1):163\u201383. https:\/\/doi.org\/10.1111\/rssb.12301.","journal-title":"J R Stat Soc Ser B"},{"key":"1672_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3762651","author":"I Unal","year":"2017","unstructured":"Unal I. Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach. Comput Math Methods Med. 2017;2017:3762651. https:\/\/doi.org\/10.1155\/2017\/3762651.","journal-title":"Comput Mathemat Methods Med"},{"key":"1672_CR35","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/liv.14430","volume":"40","author":"L Valenti","year":"2020","unstructured":"Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int: official Journal of the International Association for the Study of the Liver. 2020;40:1016\u20137.","journal-title":"Liver Int: official Journal of the International Association for the Study of the Liver"},{"issue":"4","key":"1672_CR36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hep4.1155","volume":"2","author":"YY Zhou","year":"2018","unstructured":"Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun. 2018;2(4):376\u201392.","journal-title":"Hepatol Commun"},{"key":"1672_CR37","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hep4.1155","volume":"2","author":"Y-Y Zhou","year":"2018","unstructured":"Zhou Y-Y, Zhou X-D, Wu S-J, Fan D-H, Van PS, Chen Y-P, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun. 2018;2:376\u201392.","journal-title":"Hepatol Commun"},{"key":"1672_CR38","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/gutjnl-2018-317666","volume":"68","author":"Y Chang","year":"2019","unstructured":"Chang Y, Ryu S, Sung K-C, Kyun Y, Sung E, Kim H-N, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung health study. Gut. 2019;68:1667\u201375.","journal-title":"Gut"},{"issue":"6","key":"1672_CR39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MEG.0000000000001075","volume":"30","author":"Y-Y Zhou","year":"2018","unstructured":"Zhou Y-Y, Zhou X-D, Wu S-J, Hu X-Q, Tang B, van Poucke S, et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(6):631\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10106","key":"1672_CR40","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","volume":"390","author":"M Metra","year":"2017","unstructured":"Metra M, Teerlink JR. Heart failure. Lancet (London, England). 2017;390(10106):1981\u201395.","journal-title":"Lancet (London, England)"},{"issue":"8","key":"1672_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution. Eur J Heart Fail. 2016;18(8):891\u2013975.","journal-title":"Eur J Heart Fail."},{"issue":"18","key":"1672_CR42","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/eurheartj\/ehi291","volume":"26","author":"FH Rutten","year":"2005","unstructured":"Rutten FH, Cramer M-JM, Grobbee DE, Sachs APE, Kirkels JH, Lammers J-WJ, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887\u201394.","journal-title":"Eur Heart J"},{"issue":"8","key":"1672_CR43","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","volume":"55","author":"LJM Boonman-de Winter","year":"2012","unstructured":"Boonman-de Winter LJM, Rutten FH, Cramer MJM, Landman MJ, Liem AH, Rutten GEHM, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154\u201362. https:\/\/doi.org\/10.1007\/s00125-012-2579-0.","journal-title":"Diabetologia"},{"issue":"1","key":"1672_CR44","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/s41598-022-06333-1","volume":"12","author":"T Oh","year":"2022","unstructured":"Oh T, Kim D, Lee S, Won C, Kim S, Yang J, et al. Machine learning-based diagnosis and risk factor analysis of cardiocerebrovascular disease based on KNHANES. Sci Rep. 2022;12(1):2250. https:\/\/doi.org\/10.1038\/s41598-022-06333-1.","journal-title":"Sci Rep"},{"issue":"5","key":"1672_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213653","volume":"14","author":"AM Alaa","year":"2019","unstructured":"Alaa AM, Bolton T, Di Angelantonio E, Rudd JHF, van der Schaar M. Cardiovascular disease risk prediction using automated machine learning: a prospective study of 423,604 UK Biobank participants. PLoS ONE. 2019;14(5): e0213653.","journal-title":"PLoS ONE"},{"key":"1672_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","volume":"55","author":"WB Kannel","year":"1961","unstructured":"Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease\u2013six year follow-up experience the Framingham study. Ann Intern Med. 1961;55:33\u201350.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1672_CR47","doi-asserted-by":"publisher","first-page":"e011701","DOI":"10.1161\/CIRCIMAGING.120.011701","volume":"14","author":"A Mehta","year":"2021","unstructured":"Mehta A, Rigdon J, Tattersall MC, German CA, Barringer TA, Joshi PH, et al. Association of carotid artery plaque with cardiovascular events and incident coronary artery calcium in individuals with absent coronary calcification. Circ Cardiovasc Imaging. 2021;14(4):e011701. https:\/\/doi.org\/10.1161\/CIRCIMAGING.120.011701.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"1672_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2337\/cd22-as01","volume":"40","author":"AD Association","year":"2022","unstructured":"Association AD. Standards of medical care in diabetes\u20142022 abridged for primary care providers. Clin Diabetes. 2022;40(1):10\u201338. https:\/\/doi.org\/10.2337\/cd22-as01.","journal-title":"Clin Diabetes"},{"issue":"2","key":"1672_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Associ. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"7","key":"1672_CR50","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacc.2013.09.063","volume":"63","author":"Y Ben-Shlomo","year":"2014","unstructured":"Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1672_CR51","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart association\/American Stroke Association. Stroke. 2021;52(7):e364-467.","journal-title":"Stroke"},{"issue":"5","key":"1672_CR52","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/S2214-109X(20)30132-7","volume":"8","author":"JH Joh","year":"2020","unstructured":"Joh JH, Cho S. Cardiovascular risk of carotid atherosclerosis: global consensus beyond societal guidelines. Lancet Glob Heal. 2020;8(5):e625\u20136.","journal-title":"Lancet Glob Heal"},{"issue":"5","key":"1672_CR53","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jama.2020.26988","volume":"325","author":"AH Krist","year":"2021","unstructured":"Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. Screening for asymptomatic carotid artery stenosis: US preventive services task force recommendation statement. JAMA. 2021;325(5):476\u201381.","journal-title":"JAMA"},{"key":"1672_CR54","doi-asserted-by":"crossref","unstructured":"Bosowski P, Bosowska J, Nalepa J. Evolving Deep Ensembles For Detecting Covid-19 In Chest X-Rays. In: 2021 IEEE International Conference on Image Processing (ICIP). 2021. p. 3772\u20136.","DOI":"10.1109\/ICIP42928.2021.9506119"},{"issue":"1","key":"1672_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40537-019-0276-2","volume":"6","author":"SS Yadav","year":"2019","unstructured":"Yadav SS, Jadhav SM. Deep convolutional neural network based medical image classification for disease diagnosis. J Big Data. 2019;6(1):113. https:\/\/doi.org\/10.1186\/s40537-019-0276-2.","journal-title":"J Big Data"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01672-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01672-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01672-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T06:04:41Z","timestamp":1668319481000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01672-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1672"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01672-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Every patient signed an informed consent agreement for participation in the study. The study protocol obtained the approval of the Ethics Committee by the Medical University of Silesia (KNW\/0022\/KB1\/38\/I\/17).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}